Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole genome CRISPRi screening identifies druggable vulnerabilities in drug-resistant Mycobacterium tuberculosis

ABSTRACT:

Tuberculosis (TB) remains a global health threat, aggravated by the emergence of drug-resistant strains. This study aims to identify genes and metabolic pathways with increased vulnerability in drug-resistant Mycobacterium tuberculosis strains compared to their drug-susceptible counterparts. Using CRISPR interference (CRISPRi), we screened for critical pathways unique or shared across resistant strains. The findings reveal potential therapeutic targets, offering new avenues for anti-TB drug development. This approach addresses the urgent need for effective treatments against drug-resistant TB and advances our understanding of its underlying resistance mechanisms. This work highlights how changes in the physiology of drug-resistant strains generate druggable vulnerabilities that can be exploited to improve clinical outcomes.

INSTRUMENT(S): Liquid Chromatography MS -

PROVIDER: MTBLS11277 | MetaboLights | 2024-10-15

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MM_01_WT_R1.mzML	Mzml
	MM_01_WT_R1.raw	Raw
	MM_02_INH-1_R1.mzML	Mzml
	MM_02_INH-1_R1.raw	Raw
	MM_11_buffer_2.mzML	Mzml

Items per page:

1 - 5 of 72

Similar Datasets

Whole Genome Sequence Analysis of Mycobacterium tuberculosis Strains from Patients in Campania Region

Project description:Tuberculosis (TB) is one of the deadliest infectious disorders in the world. To effectively TB manage, an essential step is to gain insight into the lineage of Mycobacterium tuberculosis (MTB) strains and the distribution of drug resistance. Although the Campania region is declared a cluster area for the infection, to contribute to the effort to understand TB evolution and transmission, still poorly known, we have generated a dataset of 159 genomes of MTB strains, from Campania region collected during 2018-2021, obtained from the analysis of whole genome sequence data. The results show that the most frequent MTB lineage is the 4 according for 129 strains (81.11%). Regarding drug resistance, 139 strains (87.4%) were classified as multi susceptible, while the remaining 20 (12.58%) showed drug resistance. Among the drug-resistance strains, 8 were isoniazid-resistant MTB (HR-MTB), 7 were resistant only to one antibiotic (3 were resistant only to ethambutol and 3 isolate to streptomycin while one isolate showed resistance to fluoroquinolones), 4 multidrug-resistant MTB, while only one was classified as pre-extensively drug-resistant MTB (pre-XDR). This dataset expands the existing available knowledge on drug resistance and evolution of MTB, contributing to further TB-related genomics studies to improve the management of TB infection.

2023-11-17 | E-MTAB-13058 | biostudies-arrayexpress

Lefamulin: A Novel Pleuromutilin Effective Against Mycobacterium tuberculosis via Efflux Inhibition

Project description:Tuberculosis (TB) remains a major global health challenge, exacerbated by the increasing prevalence of drug-resistant strains. Drug repurposing is a crucial strategy for TB control, particularly in combating resistance. Through this approach, the anti-TB potential of lefamulin was identified as a candidate for systemic administration. Lefamulin demonstrates potent inhibitory activity against Mycobacterium tuberculosis (M.tb) in vitro , in vivo, and within intracellular environments. Notably, it exhibits synergistic effects when combined with the first-line anti-TB drugs rifampicin and isoniazid, as demonstrated in insect model.

2025-06-04 | GSE280850 | GEO

Vitamin C Stimulon in Mycobacterium tuberculosis

Project description:The emergence of drug resistance among tuberculosis (TB) patients is often associated with their non-compliance to the length of the chemotherapy, which can reach up to 2 years for the treatment of multi-drug-resistant (MDR) TB. Drugs that would kill TB faster and would not lead to the development of drug resistance could shorten chemotherapy significantly. In Escherichia coli, the common mechanism of cell death by bactericidal antibiotics is the generation of highly reactive hydroxyl radicals via the Fenton reaction. Since ascorbic acid (vitamin C) is known to drive the Fenton reaction, we tested whether the Fenton reaction could lead to a bactericidal event in Mycobacterium tuberculosis by treating M. tuberculosis cultures with vitamin C. Here, we report that the addition of vitamin C to drug-susceptible, MDR and extensively drug-resistant (XDR) M. tuberculosis strains results in sterilization of the cultures in vitro. We show that the sterilizing effect of vitamin C on M. tuberculosis was dependent on the production of high ferrous ion levels and reactive oxygen species. Although, this potent sterilizing activity of vitamin C against M. tuberculosis in vitro was not observed in mice, we believe this activity needs further investigation. Comparison of vitamin C treated Mycobacterium tuberculosis transcriptome relative to untreated; Three biological replicates, second is a dye flip

2013-05-24 | E-GEOD-42293 | biostudies-arrayexpress

Vitamin C Stimulon in Mycobacterium tuberculosis

2013-05-24 | GSE42293 | GEO

Mycobacterium tuberculosis modified proteome under oxidative stress

Project description:Tuberculosis (TB), which is caused by Mycobacterium tuberculosis (Mtb), continues to be a public health threat. With the development and widespread of drug-resistant TB, the pressure of prevention and treatment is increasing. To determine and quantify the modified proteins, high resolution mass spectrometry were used to label and quantify the peptides and proteins modified.

2023-03-09 | PXD035802 | Pride

Mycobacterium tuberculosis clinical isolates in China: extensively drug-resistant tuberculosis vs drug sensitive one

Project description:Transcriptional profiling of mycobacterium tuberculosis clinical isolates in China comparing extensively drug-resistant tuberculosis with drug sensitive one. The same condition experiment. The samples were from the different drug-resistant strains. Only one replicate.

2009-04-04 | E-GEOD-15540 | biostudies-arrayexpress

A safe alternative to H37Rv: the attenuated double auxotroph Mycobacterium tuberculosis ΔleuDΔpanCD

Project description:Currently available model organisms such as Mycobacterium smegmatis and Mycobacterium bovis Bacillus Calmette-Guérin (BCG) have significantly contributed to our understanding of tuberculosis (TB) biology, these models have limitations such as differences in genome size, growth rates and virulence. Attenuated Mycobacterium tuberculosis strains may provide more representative, safer models to study M. tuberculosis biology. For example, the M. tuberculosis ΔleuDΔpanCD double auxotroph, has undergone rigorous in vitro and in vivo safety testing. Like other auxotrophic strains, this has subsequently been approved for use in biosafety level (BSL) 2 facilities. Auxotrophic strains have been assessed as models for drug-resistant M. tuberculosis and for studying latent TB. These offer the potential as safe and useful models, but it is important to understand how well these recapitulate salient features of non-attenuated M. tuberculosis. We therefore performed a comprehensive comparison of M. tuberculosis H37Rv and M. tuberculosis ΔleuDΔpanCD. These strains demonstrated similar in vitro and intra-macrophage replication rates, similar responses to anti-TB agents and whole genome sequence conservation. Shotgun proteomics analysis suggested that M. tuberculosis ΔleuDΔpanCD has an increased propensity to enter a dormant state during acid stress, which has been verified using a dual-fluorescent replication reporter assay. Importantly, infection of human peripheral blood mononuclear cells with the 2 strains elicited comparable cytokine production, demonstrating the suitability of M. tuberculosis ΔleuDΔpanCD for immunological assays. We provide comprehensive evidence to support the judicious use of M. tuberculosis ΔleuDΔpanCD as a safe and suitable model organism for M. tuberculosis research, without the need for a BSL3 facility.

2019-07-30 | PXD013677 | Pride

Exploration of Mycobacterium tuberculosis CYP138 Function by Quantitative proteome

Project description:With the widespread of drug-resistant Mycobacterium tuberculosis (Mtb), anti-TB drugs with novel structures and targets are urgently needed to prevent the prevalence of drug-resistant strains. For the past few decades, many Mtb CYPs been structurally and functionally characterized, and some of them were proved to be potential drug targets. CYP138 belongs to the Mtb CYPs whose structures and functions are still unclear. In our study, to discover differentially expressed proteins, a cyp138-knockout strain was built, and the function of CYP138 was speculated by the comparison between cyp138-knockout and wild-type strains through 6-plex TMT-labeling-based quantitative proteomic approach.

2024-03-10 | PXD045505 | Pride

Proteomic analysis of Mycobacterium tuberculosis induced by rifampicim

Project description:Rifampicin plays an important role during tuberculosis treatment, which historically contributed for shortening therapy; however, rifampicin resistance has been the intersection for the definition of multi (MDR-TB) and extensively (XDR-TB) resistant outcomes. A key aspect which has contributed for investigations of drug action/resistance is the understanding of the dynamic genome expression, as that analyzed by Proteomics. Proteins from the reference strain, Mycobacterium tuberculosis H37Rv were extracted after 12, 24 and 48 hours over rifampicin challenge at the minimal inhibitory concentration (0.03 μg•mL-1) and identified by LC-MS.

2021-05-04 | PXD014177 | Pride

Mycobacterium tuberculosis clinical isolates in China: extensively drug-resistant tuberculosis vs drug sensitive one

Project description:Transcriptional profiling of mycobacterium tuberculosis clinical isolates in China comparing extensively drug-resistant tuberculosis with drug sensitive one.

2009-04-04 | GSE15540 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data